Share Price and Basic Stock Data
Last Updated: December 9, 2025, 8:55 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
JHS Svendgaard Laboratories Ltd operates in the personal care industry, a sector that has seen varying degrees of growth in recent years. As of the latest reporting period, the company recorded a market capitalization of ₹88.5 Cr and a trading price of ₹10.3. Revenue trends have been somewhat inconsistent; sales stood at ₹85 Cr for FY 2023, declining from ₹86 Cr in FY 2022, but showing a slight recovery to ₹92 Cr in FY 2025. The quarterly sales figures reflect this volatility, with a significant dip to ₹15.90 Cr in June 2023, followed by a rebound to ₹21.72 Cr in March 2024. Such fluctuations suggest that while the company has potential, it faces challenges in maintaining consistent revenue streams. The company’s operational focus on personal care products positions it well, but it must navigate the competitive landscape effectively to sustain growth.
Profitability and Efficiency Metrics
Profitability has been a significant concern for JHS Svendgaard. The company reported a net profit of -₹18 Cr for FY 2025, which marks a continued struggle, as evidenced by a trailing twelve-month loss of ₹20 Cr. The operating profit margins have been particularly weak, with an operating profit margin (OPM) recorded at just 7.08% in June 2025. The efficiency metrics, such as return on capital employed (ROCE), stood at a low 5.19%, indicating that the company is not utilizing its capital effectively to generate profits. The interest coverage ratio is concerning as well, at -2.01x, implying that the company is not generating sufficient earnings to cover its interest expenses. These profitability challenges highlight a pressing need for strategic operational improvements and cost management to enhance the bottom line.
Balance Sheet Strength and Financial Ratios
Examining the balance sheet reveals a mixed picture. JHS Svendgaard has reserves of ₹87 Cr and borrowings of just ₹6 Cr, which suggests a relatively low debt obligation and a strong equity position. The current ratio of 2.18 indicates that the company is well-positioned to meet its short-term liabilities, offering a cushion against financial distress. However, the price-to-book value ratio stands at 0.55x, indicating that the stock may be undervalued relative to its book value, which could attract bargain hunters. On the flip side, the return on equity (ROE) at 10.8% shows that while the company has a solid equity base, its ability to generate returns on that equity remains limited. This juxtaposition of low debt and low profitability raises questions about the company’s operational efficiency and the effectiveness of its capital allocation.
Shareholding Pattern and Investor Confidence
The shareholding structure of JHS Svendgaard reflects a significant presence of public investors, who hold approximately 63.87% of the company, while promoters hold 34.56%. This indicates a level of public interest and confidence in the company, despite its recent financial struggles. The absence of substantial foreign institutional investment (FIIs), which stands at just 1.57%, may indicate a cautious approach from global investors, potentially due to the company’s volatile profitability. The fluctuation in the number of shareholders—from 24,308 in December 2022 to 25,007 in June 2025—shows a slight recovery in investor interest, but the low participation from domestic institutional investors (DIIs) at 0% reflects a lack of institutional confidence in the stock. Overall, while the public shareholding is robust, the low institutional backing raises concerns about the long-term sustainability of investor confidence.
Outlook, Risks, and Final Insight
Looking ahead, JHS Svendgaard Laboratories faces both opportunities and challenges. The personal care market continues to grow, driven by rising consumer awareness and demand for quality products. However, the company’s recent financial performance raises significant risks. The persistent net losses and low operating margins suggest that it may struggle to compete effectively unless operational efficiencies are improved. Additionally, the lack of institutional investment could hinder its ability to raise funds for expansion or innovation. Investors should weigh these risks against the potential for recovery in revenue and profitability. A strategic turnaround could enhance investor sentiment, but caution is warranted given the current financial metrics. As such, while the stock may appear undervalued, investors should consider the broader market dynamics and the company’s ability to execute a successful turnaround before making any decisions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of JHS Svendgaard Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Honasa Consumer Ltd | 8,477 Cr. | 261 | 334/190 | 68.1 | 38.8 | 0.00 % | 7.44 % | 5.51 % | 10.0 |
| Ambica Agarbathies Aroma & Industries Ltd | 43.8 Cr. | 25.3 | 37.0/23.3 | 85.9 | 65.2 | 0.00 % | 7.49 % | 0.45 % | 10.0 |
| Ador Multi Products Ltd | 123 Cr. | 129 | 134/23.4 | 32.5 | 0.00 % | 11.4 % | 3.09 % | 10.0 | |
| Kaya Ltd | 537 Cr. | 356 | 488/204 | 60.9 | 0.00 % | 2.50 % | % | 10.0 | |
| Jyothy Labs Ltd | 10,512 Cr. | 286 | 423/268 | 28.7 | 55.8 | 1.22 % | 24.6 % | 19.0 % | 1.00 |
| Industry Average | 68,867.14 Cr | 1,893.86 | 57.42 | 112.70 | 0.76% | 29.21% | 23.91% | 4.94 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.31 | 21.05 | 22.19 | 21.72 | 15.90 | 18.93 | 14.30 | 21.66 | 24.48 | 19.68 | 22.66 | 25.17 | 23.45 |
| Expenses | 22.77 | 23.02 | 24.41 | 25.28 | 18.02 | 18.52 | 14.36 | 20.82 | 22.51 | 20.52 | 22.41 | 30.55 | 21.79 |
| Operating Profit | -1.46 | -1.97 | -2.22 | -3.56 | -2.12 | 0.41 | -0.06 | 0.84 | 1.97 | -0.84 | 0.25 | -5.38 | 1.66 |
| OPM % | -6.85% | -9.36% | -10.00% | -16.39% | -13.33% | 2.17% | -0.42% | 3.88% | 8.05% | -4.27% | 1.10% | -21.37% | 7.08% |
| Other Income | 1.48 | 2.52 | 0.94 | -11.54 | 0.41 | 0.20 | 2.34 | 1.37 | 0.32 | 0.86 | 0.27 | -1.44 | 1.00 |
| Interest | 0.68 | 0.12 | 0.16 | 0.11 | 0.13 | 0.10 | 0.11 | 0.13 | 0.12 | 0.11 | 0.13 | 0.21 | 0.16 |
| Depreciation | 1.70 | 1.49 | 1.46 | 1.61 | 1.32 | 1.50 | 1.63 | 1.90 | 1.97 | 1.98 | 1.97 | 2.02 | 1.88 |
| Profit before tax | -2.36 | -1.06 | -2.90 | -16.82 | -3.16 | -0.99 | 0.54 | 0.18 | 0.20 | -2.07 | -1.58 | -9.05 | 0.62 |
| Tax % | 75.85% | -13.21% | -4.83% | -36.39% | -18.35% | -26.26% | 100.00% | 516.67% | 415.00% | 398.07% | 15.82% | -23.09% | -69.35% |
| Net Profit | -4.16 | -0.92 | -2.76 | -10.71 | -2.59 | -0.73 | 0.01 | -0.75 | -0.63 | -10.32 | -1.84 | -6.96 | 1.06 |
| EPS in Rs | -0.59 | -0.14 | -0.43 | -1.65 | -0.40 | -0.09 | 0.00 | -0.10 | -0.08 | -1.21 | -0.21 | -0.81 | 0.12 |
Last Updated: August 20, 2025, 8:40 am
Below is a detailed analysis of the quarterly data for JHS Svendgaard Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 23.45 Cr.. The value appears to be declining and may need further review. It has decreased from 25.17 Cr. (Mar 2025) to 23.45 Cr., marking a decrease of 1.72 Cr..
- For Expenses, as of Jun 2025, the value is 21.79 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 30.55 Cr. (Mar 2025) to 21.79 Cr., marking a decrease of 8.76 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.66 Cr.. The value appears strong and on an upward trend. It has increased from -5.38 Cr. (Mar 2025) to 1.66 Cr., marking an increase of 7.04 Cr..
- For OPM %, as of Jun 2025, the value is 7.08%. The value appears strong and on an upward trend. It has increased from -21.37% (Mar 2025) to 7.08%, marking an increase of 28.45%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from -1.44 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 2.44 Cr..
- For Interest, as of Jun 2025, the value is 0.16 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.21 Cr. (Mar 2025) to 0.16 Cr., marking a decrease of 0.05 Cr..
- For Depreciation, as of Jun 2025, the value is 1.88 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.02 Cr. (Mar 2025) to 1.88 Cr., marking a decrease of 0.14 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.62 Cr.. The value appears strong and on an upward trend. It has increased from -9.05 Cr. (Mar 2025) to 0.62 Cr., marking an increase of 9.67 Cr..
- For Tax %, as of Jun 2025, the value is -69.35%. The value appears to be improving (decreasing) as expected. It has decreased from -23.09% (Mar 2025) to -69.35%, marking a decrease of 46.26%.
- For Net Profit, as of Jun 2025, the value is 1.06 Cr.. The value appears strong and on an upward trend. It has increased from -6.96 Cr. (Mar 2025) to 1.06 Cr., marking an increase of 8.02 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.12. The value appears strong and on an upward trend. It has increased from -0.81 (Mar 2025) to 0.12, marking an increase of 0.93.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:04 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 35 | 55 | 100 | 104 | 140 | 124 | 139 | 101 | 86 | 85 | 71 | 92 | 91 |
| Expenses | 39 | 59 | 93 | 92 | 126 | 124 | 137 | 99 | 87 | 94 | 72 | 96 | 95 |
| Operating Profit | -4 | -4 | 7 | 12 | 14 | 0 | 2 | 2 | -1 | -9 | -1 | -4 | -4 |
| OPM % | -11% | -7% | 7% | 11% | 10% | 0% | 1% | 2% | -1% | -11% | -1% | -4% | -5% |
| Other Income | -3 | -6 | -17 | 0 | 32 | 6 | 3 | 7 | 9 | -7 | 4 | 0 | 1 |
| Interest | 14 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 1 |
| Depreciation | 15 | 12 | 10 | 6 | 7 | 7 | 9 | 7 | 7 | 6 | 6 | 8 | 8 |
| Profit before tax | -35 | -22 | -22 | 5 | 38 | -2 | -6 | 1 | 0 | -23 | -3 | -13 | -12 |
| Tax % | -18% | 0% | 0% | -327% | 32% | -19% | -17% | -39% | 4,000% | -24% | 18% | 58% | |
| Net Profit | -29 | -22 | -22 | 22 | 26 | -2 | -5 | 1 | -4 | -18 | -4 | -20 | -18 |
| EPS in Rs | -11.95 | -9.20 | -5.76 | 4.98 | 4.29 | -0.11 | -0.33 | 0.19 | -0.62 | 0.62 | -0.52 | -2.31 | -2.11 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 24.14% | 0.00% | 200.00% | 18.18% | -107.69% | -150.00% | 120.00% | -500.00% | -350.00% | 77.78% | -400.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -24.14% | 200.00% | -181.82% | -125.87% | -42.31% | 270.00% | -620.00% | 150.00% | 427.78% | -477.78% |
JHS Svendgaard Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | -8% |
| 3 Years: | 2% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -624% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -9% |
| 3 Years: | -23% |
| 1 Year: | -61% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| Last Year: | -11% |
Last Updated: September 5, 2025, 8:15 am
Balance Sheet
Last Updated: December 10, 2025, 2:54 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24.10 | 24.10 | 37.64 | 44.12 | 60.90 | 60.90 | 60.90 | 64.40 | 64.90 | 78.40 | 78.40 | 85.60 | 85.60 |
| Reserves | 38.01 | 95.50 | 62.95 | 90.25 | 113.36 | 115.94 | 117.10 | 124.30 | 121.00 | 95.44 | 91.49 | 87.12 | 88.04 |
| Borrowings | 54.12 | 18.82 | 2.56 | 2.31 | 2.49 | 7.19 | 8.58 | 7.01 | 6.19 | 2.58 | 5.13 | 6.46 | 10.59 |
| Other Liabilities | 74.19 | 32.93 | 19.26 | 18.57 | 31.59 | 38.54 | 54.88 | 32.72 | 30.01 | 51.81 | 22.04 | 24.62 | 22.67 |
| Total Liabilities | 190.42 | 171.35 | 122.41 | 155.25 | 208.34 | 222.57 | 241.46 | 228.43 | 222.10 | 228.23 | 197.06 | 203.80 | 206.90 |
| Fixed Assets | 120.88 | 107.89 | 65.10 | 65.00 | 71.41 | 70.81 | 65.63 | 63.22 | 58.52 | 65.07 | 90.41 | 90.33 | 88.32 |
| CWIP | 0.03 | 0.03 | 0.68 | 0.67 | 0.51 | 4.80 | 7.05 | 8.92 | 19.96 | 8.57 | 0.82 | 0.00 | 2.95 |
| Investments | 0.00 | 0.00 | 0.00 | 1.03 | 18.19 | 9.75 | 6.03 | 2.05 | 3.62 | 2.97 | 3.45 | 3.64 | 4.88 |
| Other Assets | 69.51 | 63.43 | 56.63 | 88.55 | 118.23 | 137.21 | 162.75 | 154.24 | 140.00 | 151.62 | 102.38 | 109.83 | 110.75 |
| Total Assets | 190.42 | 171.35 | 122.41 | 155.25 | 208.34 | 222.57 | 241.46 | 228.43 | 222.10 | 228.23 | 197.06 | 203.80 | 206.90 |
Below is a detailed analysis of the balance sheet data for JHS Svendgaard Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 85.60 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 85.60 Cr..
- For Reserves, as of Sep 2025, the value is 88.04 Cr.. The value appears strong and on an upward trend. It has increased from 87.12 Cr. (Mar 2025) to 88.04 Cr., marking an increase of 0.92 Cr..
- For Borrowings, as of Sep 2025, the value is 10.59 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 6.46 Cr. (Mar 2025) to 10.59 Cr., marking an increase of 4.13 Cr..
- For Other Liabilities, as of Sep 2025, the value is 22.67 Cr.. The value appears to be improving (decreasing). It has decreased from 24.62 Cr. (Mar 2025) to 22.67 Cr., marking a decrease of 1.95 Cr..
- For Total Liabilities, as of Sep 2025, the value is 206.90 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 203.80 Cr. (Mar 2025) to 206.90 Cr., marking an increase of 3.10 Cr..
- For Fixed Assets, as of Sep 2025, the value is 88.32 Cr.. The value appears to be declining and may need further review. It has decreased from 90.33 Cr. (Mar 2025) to 88.32 Cr., marking a decrease of 2.01 Cr..
- For CWIP, as of Sep 2025, the value is 2.95 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 2.95 Cr., marking an increase of 2.95 Cr..
- For Investments, as of Sep 2025, the value is 4.88 Cr.. The value appears strong and on an upward trend. It has increased from 3.64 Cr. (Mar 2025) to 4.88 Cr., marking an increase of 1.24 Cr..
- For Other Assets, as of Sep 2025, the value is 110.75 Cr.. The value appears strong and on an upward trend. It has increased from 109.83 Cr. (Mar 2025) to 110.75 Cr., marking an increase of 0.92 Cr..
- For Total Assets, as of Sep 2025, the value is 206.90 Cr.. The value appears strong and on an upward trend. It has increased from 203.80 Cr. (Mar 2025) to 206.90 Cr., marking an increase of 3.10 Cr..
Notably, the Reserves (88.04 Cr.) exceed the Borrowings (10.59 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -58.00 | -23.00 | 4.00 | 10.00 | 12.00 | -7.00 | -7.00 | -5.00 | -7.00 | -12.00 | -6.00 | -10.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 188 | 167 | 25 | 48 | 111 | 158 | 252 | 213 | 77 | 80 | 66 | 52 |
| Inventory Days | 122 | 94 | 53 | 95 | 65 | 60 | 30 | 97 | 114 | 128 | 176 | 153 |
| Days Payable | 95 | 106 | 67 | 123 | 153 | 134 | 177 | 128 | 130 | 197 | 197 | 141 |
| Cash Conversion Cycle | 215 | 156 | 12 | 19 | 23 | 85 | 105 | 182 | 61 | 11 | 46 | 63 |
| Working Capital Days | -708 | -39 | 58 | 56 | 122 | 173 | 198 | 272 | 217 | 41 | 51 | 48 |
| ROCE % | -10% | -12% | -3% | 5% | 8% | -0% | 4% | 1% | 1% | -2% | -2% | -5% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -2.37 | -0.52 | -2.34 | -0.63 | 0.20 |
| Diluted EPS (Rs.) | -2.37 | -0.52 | -2.34 | -0.63 | 0.20 |
| Cash EPS (Rs.) | -1.38 | 0.29 | -1.43 | 0.42 | 1.33 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 20.18 | 21.67 | 27.78 | 30.05 | 30.74 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 20.18 | 21.67 | 27.78 | 30.05 | 30.74 |
| Revenue From Operations / Share (Rs.) | 10.75 | 9.03 | 14.82 | 13.29 | 15.65 |
| PBDIT / Share (Rs.) | -0.13 | 0.43 | 0.81 | 1.32 | 1.47 |
| PBIT / Share (Rs.) | -1.06 | -0.37 | -0.33 | 0.23 | 0.34 |
| PBT / Share (Rs.) | -1.46 | -0.43 | -3.37 | 0.01 | 0.15 |
| Net Profit / Share (Rs.) | -2.31 | -0.51 | -2.58 | -0.66 | 0.20 |
| NP After MI And SOA / Share (Rs.) | -2.31 | -0.51 | -2.38 | -0.62 | 0.18 |
| PBDIT Margin (%) | -1.23 | 4.77 | 5.50 | 9.91 | 9.39 |
| PBIT Margin (%) | -9.87 | -4.19 | -2.25 | 1.73 | 2.19 |
| PBT Margin (%) | -13.59 | -4.84 | -22.70 | 0.11 | 0.96 |
| Net Profit Margin (%) | -21.46 | -5.73 | -17.43 | -4.97 | 1.33 |
| NP After MI And SOA Margin (%) | -21.46 | -5.73 | -16.07 | -4.69 | 1.18 |
| Return on Networth / Equity (%) | -11.43 | -2.38 | -8.96 | -2.17 | 0.63 |
| Return on Capital Employeed (%) | -5.14 | -1.70 | -1.09 | 0.73 | 1.07 |
| Return On Assets (%) | -9.81 | -2.05 | -6.54 | -1.82 | 0.52 |
| Total Debt / Equity (X) | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.46 | 0.32 | 0.41 | 0.36 | 0.42 |
| Current Ratio (X) | 2.18 | 1.87 | 2.36 | 4.18 | 5.23 |
| Quick Ratio (X) | 1.70 | 1.33 | 2.00 | 3.54 | 4.73 |
| Inventory Turnover Ratio (X) | 7.50 | 3.11 | 4.36 | 5.16 | 8.94 |
| Interest Coverage Ratio (X) | -2.01 | 7.34 | 5.09 | 6.13 | 7.63 |
| Interest Coverage Ratio (Post Tax) (X) | -28.88 | -7.82 | 2.78 | -2.08 | 2.08 |
| Enterprise Value (Cr.) | 81.22 | 121.69 | 70.51 | 136.74 | 117.07 |
| EV / Net Operating Revenue (X) | 0.88 | 1.72 | 0.73 | 1.59 | 1.16 |
| EV / EBITDA (X) | -71.68 | 36.03 | 13.31 | 15.99 | 12.37 |
| MarketCap / Net Operating Revenue (X) | 1.04 | 1.81 | 1.06 | 1.55 | 1.27 |
| Price / BV (X) | 0.55 | 0.75 | 0.59 | 0.71 | 0.68 |
| Price / Net Operating Revenue (X) | 1.04 | 1.81 | 1.06 | 1.55 | 1.27 |
| EarningsYield | -0.20 | -0.03 | -0.15 | -0.03 | 0.01 |
After reviewing the key financial ratios for JHS Svendgaard Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -2.37. This value is below the healthy minimum of 5. It has decreased from -0.52 (Mar 24) to -2.37, marking a decrease of 1.85.
- For Diluted EPS (Rs.), as of Mar 25, the value is -2.37. This value is below the healthy minimum of 5. It has decreased from -0.52 (Mar 24) to -2.37, marking a decrease of 1.85.
- For Cash EPS (Rs.), as of Mar 25, the value is -1.38. This value is below the healthy minimum of 3. It has decreased from 0.29 (Mar 24) to -1.38, marking a decrease of 1.67.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.18. It has decreased from 21.67 (Mar 24) to 20.18, marking a decrease of 1.49.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.18. It has decreased from 21.67 (Mar 24) to 20.18, marking a decrease of 1.49.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 10.75. It has increased from 9.03 (Mar 24) to 10.75, marking an increase of 1.72.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.13. This value is below the healthy minimum of 2. It has decreased from 0.43 (Mar 24) to -0.13, marking a decrease of 0.56.
- For PBIT / Share (Rs.), as of Mar 25, the value is -1.06. This value is below the healthy minimum of 0. It has decreased from -0.37 (Mar 24) to -1.06, marking a decrease of 0.69.
- For PBT / Share (Rs.), as of Mar 25, the value is -1.46. This value is below the healthy minimum of 0. It has decreased from -0.43 (Mar 24) to -1.46, marking a decrease of 1.03.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -2.31. This value is below the healthy minimum of 2. It has decreased from -0.51 (Mar 24) to -2.31, marking a decrease of 1.80.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -2.31. This value is below the healthy minimum of 2. It has decreased from -0.51 (Mar 24) to -2.31, marking a decrease of 1.80.
- For PBDIT Margin (%), as of Mar 25, the value is -1.23. This value is below the healthy minimum of 10. It has decreased from 4.77 (Mar 24) to -1.23, marking a decrease of 6.00.
- For PBIT Margin (%), as of Mar 25, the value is -9.87. This value is below the healthy minimum of 10. It has decreased from -4.19 (Mar 24) to -9.87, marking a decrease of 5.68.
- For PBT Margin (%), as of Mar 25, the value is -13.59. This value is below the healthy minimum of 10. It has decreased from -4.84 (Mar 24) to -13.59, marking a decrease of 8.75.
- For Net Profit Margin (%), as of Mar 25, the value is -21.46. This value is below the healthy minimum of 5. It has decreased from -5.73 (Mar 24) to -21.46, marking a decrease of 15.73.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -21.46. This value is below the healthy minimum of 8. It has decreased from -5.73 (Mar 24) to -21.46, marking a decrease of 15.73.
- For Return on Networth / Equity (%), as of Mar 25, the value is -11.43. This value is below the healthy minimum of 15. It has decreased from -2.38 (Mar 24) to -11.43, marking a decrease of 9.05.
- For Return on Capital Employeed (%), as of Mar 25, the value is -5.14. This value is below the healthy minimum of 10. It has decreased from -1.70 (Mar 24) to -5.14, marking a decrease of 3.44.
- For Return On Assets (%), as of Mar 25, the value is -9.81. This value is below the healthy minimum of 5. It has decreased from -2.05 (Mar 24) to -9.81, marking a decrease of 7.76.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.46. It has increased from 0.32 (Mar 24) to 0.46, marking an increase of 0.14.
- For Current Ratio (X), as of Mar 25, the value is 2.18. This value is within the healthy range. It has increased from 1.87 (Mar 24) to 2.18, marking an increase of 0.31.
- For Quick Ratio (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.33 (Mar 24) to 1.70, marking an increase of 0.37.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.50. This value is within the healthy range. It has increased from 3.11 (Mar 24) to 7.50, marking an increase of 4.39.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -2.01. This value is below the healthy minimum of 3. It has decreased from 7.34 (Mar 24) to -2.01, marking a decrease of 9.35.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -28.88. This value is below the healthy minimum of 3. It has decreased from -7.82 (Mar 24) to -28.88, marking a decrease of 21.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 81.22. It has decreased from 121.69 (Mar 24) to 81.22, marking a decrease of 40.47.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1. It has decreased from 1.72 (Mar 24) to 0.88, marking a decrease of 0.84.
- For EV / EBITDA (X), as of Mar 25, the value is -71.68. This value is below the healthy minimum of 5. It has decreased from 36.03 (Mar 24) to -71.68, marking a decrease of 107.71.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.81 (Mar 24) to 1.04, marking a decrease of 0.77.
- For Price / BV (X), as of Mar 25, the value is 0.55. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.55, marking a decrease of 0.20.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.81 (Mar 24) to 1.04, marking a decrease of 0.77.
- For EarningsYield, as of Mar 25, the value is -0.20. This value is below the healthy minimum of 5. It has decreased from -0.03 (Mar 24) to -0.20, marking a decrease of 0.17.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in JHS Svendgaard Laboratories Ltd:
- Net Profit Margin: -21.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -5.14% (Industry Average ROCE: 29.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -11.43% (Industry Average ROE: 23.91%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -28.88
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.7
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 57.42)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -21.46%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Personal Care | Trilokpur Road, Kheri (Kala Amb), Sirmour Dist. Himachal Pradesh 173030 | cs@svendgaard.com http://www.svendgaard.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajagopal Chakravarthi Venkateish | Chairman & Ind.Director |
| Mr. Nikhil Nanda | Managing & Executive Director |
| Mr. Vinay Mittal | Non Executive Director |
| Mr. Kapil Minocha | Independent Director |
| Mrs. Upma Chawdhry | Independent Woman Director |
FAQ
What is the intrinsic value of JHS Svendgaard Laboratories Ltd?
JHS Svendgaard Laboratories Ltd's intrinsic value (as of 09 December 2025) is 26.83 which is 157.98% higher the current market price of 10.40, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 90.0 Cr. market cap, FY2025-2026 high/low of 24.9/9.90, reserves of ₹87 Cr, and liabilities of 204 Cr.
What is the Market Cap of JHS Svendgaard Laboratories Ltd?
The Market Cap of JHS Svendgaard Laboratories Ltd is 90.0 Cr..
What is the current Stock Price of JHS Svendgaard Laboratories Ltd as on 09 December 2025?
The current stock price of JHS Svendgaard Laboratories Ltd as on 09 December 2025 is 10.4.
What is the High / Low of JHS Svendgaard Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of JHS Svendgaard Laboratories Ltd stocks is 24.9/9.90.
What is the Stock P/E of JHS Svendgaard Laboratories Ltd?
The Stock P/E of JHS Svendgaard Laboratories Ltd is .
What is the Book Value of JHS Svendgaard Laboratories Ltd?
The Book Value of JHS Svendgaard Laboratories Ltd is 20.3.
What is the Dividend Yield of JHS Svendgaard Laboratories Ltd?
The Dividend Yield of JHS Svendgaard Laboratories Ltd is 0.00 %.
What is the ROCE of JHS Svendgaard Laboratories Ltd?
The ROCE of JHS Svendgaard Laboratories Ltd is 5.19 %.
What is the ROE of JHS Svendgaard Laboratories Ltd?
The ROE of JHS Svendgaard Laboratories Ltd is 10.8 %.
What is the Face Value of JHS Svendgaard Laboratories Ltd?
The Face Value of JHS Svendgaard Laboratories Ltd is 10.0.